| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2006-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008539794-A |
| titleOfInvention |
Methods for the diagnosis and treatment of proliferative disorders mediated by CD40 signaling |
| abstract |
Methods are provided for identifying a subject with a cancer or pre-cancerous condition that would benefit from an anti-CD40 therapeutic that modulates CD40L-mediated CD40 signaling. This method is intended to monitor ex vivo responses to one or more anti-CD40 therapeutics of interest that modulate CD40 signaling on CD40-expressing neoplastic cells to monitor cell apoptosis, cell proliferation and survival and CD40 signaling. Includes the use of pathway biomarkers. The ex vivo prognostic assay may be used alone or in combination with other prognostic assays to identify candidate subjects that would benefit from treatment with an anti-CD40 therapeutic. The methods of the invention also include the use of these biomarkers to monitor the in vivo efficacy of treatment with anti-CD40 therapeutics. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9822339-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014500726-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012523838-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9068230-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10611829-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9969795-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009539081-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10077427-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10344076-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10774308-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10273454-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9617600-B2 |
| priorityDate |
2005-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |